This class of agents might be useful in the treatment of HER2- and EGFR-dependent breast tumors and may be effective for the treatment of cancers that have acquired resistance to monoclonal antibodies or tyrosine kinase inhibitors targeting these enzymes. Here, ERBB2 is linked to breast neoplasm.